2.4646

1.86% 0.0446

Abcellera Biologics Inc (ABCL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ABCL? Forum Prognose

Schlusskurs vom Vortag:

$2.42

Offen:

$2.31

24-Stunden-Volumen:

3.30M

Relative Volume:

0.80

Marktkapitalisierung:

$727.09M

Einnahmen:

$38.03M

Nettoeinkommen (Verlust:

$-146.40M

KGV:

-4.7396

EPS:

-0.52

Netto-Cashflow:

$-121.38M

1W Leistung:

+1.02%

1M Leistung:

+1.02%

6M Leistung:

-11.01%

1J Leistung:

-36.30%

1-Tages-Spanne:

$2.31

$2.49

1-Wochen-Bereich:

$2.31

$2.53

52-Wochen-Spanne:

$1.8906

$4.3398

Abcellera Biologics Inc Stock (ABCL) Company Profile

Firmenname

Abcellera Biologics Inc

Sektor

Healthcare (1152)

Branche

Biotechnology (660)

Telefon

(604) 559-9005

Adresse

2215 YUKON STREET, VANCOUVER

Mitarbeiter

596

Twitter

Nächster Verdiensttermin

2024-11-18

Neueste SEC-Einreichungen

ABCL's Discussions on Twitter

Vergleichen Sie ABCL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ABCL Abcellera Biologics Inc	2.46	727.09M	38.03M	-146.40M	-121.38M	-0.52
VRTX Vertex Pharmaceuticals Inc	473.93	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	558.78	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	594.51	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	229.93	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	228.75	26.16B	3.81B	-644.79M	-669.77M	-6.24

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2024-02-22	Hochstufung	The Benchmark Company	Hold → Buy
2023-12-05	Eingeleitet	KeyBanc Capital Markets	Overweight
2023-11-06	Herabstufung	The Benchmark Company	Buy → Hold
2023-10-13	Fortgesetzt	Piper Sandler	Overweight
2023-02-28	Eingeleitet	Cowen	Outperform
2022-12-15	Eingeleitet	Goldman	Buy
2022-11-16	Eingeleitet	Truist	Buy
2021-12-21	Eingeleitet	The Benchmark Company	Buy
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-01-05	Eingeleitet	BMO Capital Markets	Outperform
2021-01-05	Eingeleitet	Berenberg	Buy
2021-01-05	Eingeleitet	Credit Suisse	Outperform
2021-01-05	Eingeleitet	SVB Leerink	Outperform
2021-01-05	Eingeleitet	Stifel	Buy

Alle ansehen

Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten

Apr 16, 2025

AbCellera Stock: Attractively Priced, But A Catalyst Is Needed (NASDAQ:ABCL) - Seeking Alpha

Apr 16, 2025

Apr 12, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June | ABCL Stock News - GuruFocus

Apr 08, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire

Apr 08, 2025

Apr 04, 2025

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace

Apr 04, 2025

Apr 01, 2025

Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India

Apr 01, 2025

Abcellera stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa

Apr 01, 2025

Mar 25, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance

Mar 25, 2025

Mar 19, 2025

AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK

Mar 19, 2025

Mar 15, 2025

AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha

Mar 15, 2025

Mar 12, 2025

What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com

Mar 12, 2025

Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa

Mar 12, 2025

Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India

Mar 12, 2025

Mar 10, 2025

Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com Australia

Mar 10, 2025

AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa

Mar 10, 2025

AbCellera biologics director John Montalbano acquires $57,499 in shares - Investing.com India

Mar 10, 2025

Mar 09, 2025

Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock - Simply Wall St

Mar 09, 2025

Mar 08, 2025

Ambarella, Builders Firstsource, Sherwin-Williams, AutoZone, AbCellera: Stock Moves That Shocked the Market - TipRanks

Mar 08, 2025

Mar 07, 2025

Director Makes Bold Move with Major Stock Purchase in AbCellera Biologics - TipRanks

Mar 07, 2025

Abcellera Biologics director Montalbano buys $140,568 in shares By Investing.com - Investing.com South Africa

Mar 07, 2025

Abcellera Biologics director Montalbano buys $140,568 in shares - Investing.com

Mar 07, 2025

Mar 06, 2025

Q1 Earnings Estimate for ABCL Issued By Bloom Burton - Defense World

Mar 06, 2025

Mar 05, 2025

Sanctuary Advisors LLC Decreases Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World

Mar 05, 2025

Mar 04, 2025

AbCellera Biologics’ (ABCL) Hold Rating Reaffirmed at Benchmark - Defense World

Mar 04, 2025

Mar 03, 2025

Benchmark maintains Hold on AbCellera stock, no price target change - Investing.com

Mar 03, 2025

Benchmark maintains Hold on AbCellera stock, no price target change By Investing.com - Investing.com UK

Mar 03, 2025

Mar 01, 2025

Stifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat

Mar 01, 2025

AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Mar 01, 2025

AbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst Downgrade - MarketBeat

Mar 01, 2025

Feb 28, 2025

AbCellera Biologics (ABCL) Projected to Post Earnings on Thursday - MarketBeat

Feb 28, 2025

AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Feb 28, 2025

AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Feb 28, 2025

AbCellera Biologics’ Earnings Call: Transition Amid Challenges - TipRanks

Feb 28, 2025

Abcellera stock hits 52-week low at $2.33 amid market challenges - Investing.com India

Feb 28, 2025